Trifluoromescaline
Mescaline derivative
From Wikipedia, the free encyclopedia
Trifluoromescaline (TFM), also known as 4-(trifluoromethoxy)-3,5-dimethoxyphenethylamine, is a derivative of the phenethylamine psychedelic mescaline, which has a 4-trifluoromethoxy group replacing the 4-methoxy group of mescaline.[2][1][3]
- None
| |
| Clinical data | |
|---|---|
| Other names | TFM; 4-(Trifluoromethoxy)-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-(trifluoromethoxy)phenethylamine |
| Routes of administration | Oral[1][2] |
| Drug class | Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 14–24 hours[1][2] |
| Identifiers | |
| |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H14F3NO3 |
| Molar mass | 265.232 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It was found to be one of the most potent compounds in the scaline series, with a reported dose of 15 to 40 mg (and 60 mg being described as a "strong overdose"), and a slow onset of action and long duration of effects, lasting 14 to 24 hours.[2]
The drug showed about 34-fold higher affinity and 36-fold greater activational potency at the serotonin 5-HT2A receptor compared to mescaline in vitro.[3] In addition, it appears to be much more lipophilic than mescaline (predicted log P = 1.9 vs. 0.7, respectively).[4][5]
Analogues of trifluoromescaline include the fluorinated scalines difluoromescaline, metadifluoromescaline, fluoroescaline, difluoroescaline, trifluoroescaline, fluoroproscaline, and trifluoroproscaline, among others. Some other analogues include the fluorinated phenethylamines 2C-TFM, DOTFM, 2C-TFE, DOTFE, 2C-T-28 (2C-T-FP), 2C-T-36 (2C-T-TFM), and 3C-DFE, among others.
TFM was first described in the scientific literature by Daniel Trachsel by 2012.[1][2] Many other related compounds have also been described by Trachsel and colleagues.[6][1][2] It is not a controlled substance in Canada as of 2025.[7]